Race Oncology Limited is pleased to announce the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett.

Race Oncology has announced it has secured a new patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office (USPTO).

Race Oncology is pleased to announce the first patient has been treated with Bisantrene in the trial at the Sheba Medical Center in Israel, without any major complications.

Race Oncology has announced the US Food and Drug Administration has received its Investigational New Drug (IND) application for the company’s cancer drug Bisantrene.

Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal Investigator for the US registration trial for Bisantrene.

Race Oncology is pleased to announce that it has executed a consulting agreement with Professor Borje Andersson from the M.D. Anderson Cancer Research Center in Houston, Texas.